{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Vincent RL"],"funding":["NIBIB NIH HHS","NCATS NIH HHS","NCI NIH HHS"],"pagination":["211-218"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10915968"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["382(6667)"],"pubmed_abstract":["A major challenge facing tumor-antigen targeting therapies such as chimeric antigen receptor (CAR)-T cells is the identification of suitable targets that are specifically and uniformly expressed on heterogeneous solid tumors. By contrast, certain species of bacteria selectively colonize immune-privileged tumor cores and can be engineered as antigen-independent platforms for therapeutic delivery. To bridge these approaches, we developed a platform of probiotic-guided CAR-T cells (ProCARs), in which tumor-colonizing probiotics release synthetic targets that label tumor tissue for CAR-mediated lysis in situ. This system demonstrated CAR-T cell activation and antigen-agnostic cell lysis that was safe and effective in multiple xenograft and syngeneic models of human and mouse cancers. We further engineered multifunctional probiotics that co-release chemokines to enhance CAR-T cell recruitment and therapeutic response."],"journal":["Science (New York, N.Y.)"],"pubmed_title":["Probiotic-guided CAR-T cells for solid tumor targeting."],"pmcid":["PMC10915968"],"funding_grant_id":["R01 EB030352","UL1 TR001873","P30 CA013696"],"pubmed_authors":["Li F","Rouanne M","Savage T","Im J","Komaranchath M","Coker C","Arpaia N","Danino T","de Los Santos-Alexis K","Vincent RL","Vardoshvili A","Gurbatri CR","Brockmann L","Ballister ER","Redenti A"],"additional_accession":[]},"is_claimable":false,"name":"Probiotic-guided CAR-T cells for solid tumor targeting.","description":"A major challenge facing tumor-antigen targeting therapies such as chimeric antigen receptor (CAR)-T cells is the identification of suitable targets that are specifically and uniformly expressed on heterogeneous solid tumors. By contrast, certain species of bacteria selectively colonize immune-privileged tumor cores and can be engineered as antigen-independent platforms for therapeutic delivery. To bridge these approaches, we developed a platform of probiotic-guided CAR-T cells (ProCARs), in which tumor-colonizing probiotics release synthetic targets that label tumor tissue for CAR-mediated lysis in situ. This system demonstrated CAR-T cell activation and antigen-agnostic cell lysis that was safe and effective in multiple xenograft and syngeneic models of human and mouse cancers. We further engineered multifunctional probiotics that co-release chemokines to enhance CAR-T cell recruitment and therapeutic response.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Oct","modification":"2025-04-26T20:15:12.233Z","creation":"2025-04-06T16:26:05.626Z"},"accession":"S-EPMC10915968","cross_references":{"pubmed":["37824640"],"doi":["10.1126/science.add7034"]}}